Evidence map›Paper›PMID 40591145›Full record

ReviewDiscover oncology2025

Increasing linc00261 expression may predict well cancer prognosis, based on the meta-analysis.

Xinyue He, Shixu Fang, Chen Wu, Jintong Na, Liping Zhong, Xiyu Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mechanistic insights into the lncRNA-Notch signaling axis in tumors.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyue He *State Key Laboratory of Targeting Oncology, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Shixu Fang *State Key Laboratory of Targeting Oncology, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Chen WuState Key Laboratory of Targeting Oncology, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Jintong NaState Key Laboratory of Targeting Oncology, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Liping ZhongState Key Laboratory of Targeting Oncology, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China. zhong_liping@163.com.
Xiyu LiuState Key Laboratory of Targeting Oncology, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China. liuxiyu0509@sr.gxmu.edu.cn.

Funding

Scientific and Technological Innovation Major Base of Guangxi No.2022-36-Z05
6 · The paper itself

Abstract

backgroundlinc00261 was reported to be deregulated in many tumor groups and was significantly associated with cancer prognosis. This investigation seeks to conduct a meta-analysis to explore the link between linc00261 levels and cancer outcomes.

methodsElectronic databases underwent comprehensive searching, and appropriate publications were filtered per the predetermined selection criteria. For each included literature, we implemented a quality assessment (NOS score) and obtained relevant data in detail. The link between linc00261 level and cancer outcomes was investigated through pooled HR and OR analysis with 95%CI. Sensitivity analysis was utilized to examine the stability and dependability of the consolidated findings. In the meantime, Begg's test was carried out to evaluate whether there exists significant publication bias or other bias in the original literature.

resultsThe linc00261 level exhibited reduction in the majority of tumor tissues, where enhanced linc00261 levels demonstrated substantial correlation with favorable cancer outcomes, encompassing overall survival (OS) (hazard ratio (HR): 0.497, 95% CI: 0.408-0.586), disease-free survival (DFS) (HR: 0.38, 95% CI: 0.25-0.59) and progression-free survival (PFS) (HR: 0.31, 95% CI: 0.18-0.53). Moreover, increased linc00261 levels indicated earlier TNM stages (odds ratio (OR): 0.542, 95%CI: 0.442-0.663), reduced susceptibility to distant lymph node metastasis (LNM) (OR: 0.674, 95%CI: 0.550-0.826), distant metastasis (DM) (OR: 0.579, 95%CI: 0.420-0.798), reduced tumor size (OR: 0.705, 95%CI: 0.564-0.880) and improved histological grade (OR: 0.906, 95%CI: 0.694-1.183). Sensitivity analysis outcomes suggest that individual studies demonstrate minimal influence on the comprehensive findings. The Begg's test outcomes suggest that the original study had no significant publication or other biases.

conclusionsThe expression of linc00261 is decreased in many tumor tissues, high linc00261 expression indicates a satisfied prognosis of cancer. linc00261 could function as a candidate therapeutic target and an encouraging prognostic indicator for tumors.

Indexed as

Cancerlinc00261Meta-analysisPrognosis

Identifiers

PMID40591145
PMCPMC12214098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.